Federal Courts Dismiss Big Pharma Lawsuits Against Medicare Drug Price Negotiations

Judges rule that pharmaceutical companies have no constitutional right to set drug prices, allowing Medicare negotiations to proceed.

Federal judges in Texas and Delaware dismiss lawsuits by Big Pharma challenging Medicare's right to negotiate drug prices.
The rulings support the Inflation Reduction Act's provision for Medicare to negotiate lower prices for prescription drugs.
Pharmaceutical companies argued that the negotiations violated their rights, but judges found the claims lacked merit.
Negotiations for lower Medicare drug prices continue, with counteroffers received for all 10 drugs initially selected.
The legal victories for Medicare negotiations may lead to more affordable prescription drugs for millions of Americans.